Podium to Practice: ESMO® 2025 – Lung: NSCLS Harboring Ex20ins /Other Uncommon Mutations

Podium to Practice: ESMO® 2025 – Lung: NSCLS Harboring Ex20ins /Other Uncommon Mutations

Podium to Practice: ESMO® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Barbara Melosky

Icon Chair Speaker

Speakers

Dr. Rosalyn Juergens

Dr. Peter Ellis

Studies / Trials Discussed

1847MO – Activity of Zipalertinib Against Active Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring EGFR Exon 20 Insertion (Ex20ins)/Other Uncommon Mutations

Studies/trials discussed:

1847MO – Activity of Zipalertinib Against Active Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring EGFR Exon 20 Insertion (Ex20ins)/Other Uncommon Mutations
Tagged